Jul. 15 at 3:12 PM
$JNJ — In Q1, management called Impella ECP a growth driver "not yet fully reflected in consensus models" and Abiomed posted 14.4% growth with an evidence base described as "absolutely solid."
This quarter: Abiomed declined 2%, driven by a neutral U.K. clinical trial on high-risk PCI increasing physician selectivity.
Schmid: "our Q2 growth is not where you wanted it, and frankly, it's not where we wanted it." Recovery expected "probably as we leave this year into next year," with PROTECT IV (1,300 patients) reading out in 2027.
On the other side: TREMFYA hit its first
$2B quarter at 71% growth, ICOTYDE launched with 18,000 prescriptions and 50%+ formulary coverage in 90 days, and guidance moved from
$100.2B to
$100.6B. #TheGapReport
